According to DelveInsight’s epidemiology model, the total incident cases of ... The recent approvals of PD-1 inhibitors like KEYTRUDA (pembrolizumab) and PARP inhibitors like LYNPARZA (olaparib ...

The company also posted a 6% year-over-year growth in total product sales, driven by an 8% increase in sales of its HIV treatment Biktarvy and a 23% rise for its oncology drug, Trodelvy.

Trodelvy’s withdrawal is one of several conditional approvals that have been rescinded in recent years, most notably among the “PD-1” class of drugs that includes Keytruda and Bristol Myers ...

Trodelvy’s next big NSCLC readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high NSCLC. Started in February 2023, the trial currently bears a ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

In a phase 3 trial, more deaths due to adverse events were reported in the Trodelvy arm compared with the chemotherapy arm. Gilead has made the decision to withdraw the accelerated approval of ...

Trodelvy's FDA approval for bladder cancer was rescinded due to unmet survival endpoints in the TROPICS-04 study. The drug remains approved for certain breast cancer treatments, highlighting its ...

But with its cell therapy unit stalling and antibody-drug conjugate Trodelvy facing challenges, the company’s oncology ambitions were brought back under the spotlight during its third-quarter ...

Gilead Sciences withdrew Trodelvy's FDA accelerated approval for urothelial cancer after the TROPiCS-04 study failed to meet the primary endpoint of overall survival. The TROPiCS-04 study showed ...

Gilead Sciences plans to voluntarily withdraw U.S. accelerated approval for Trodelvy in metastatic urothelial cancer. The decision followed results from the TROPiCS-04 study, which failed to meet ...

Trodelvy's is being evaluated in a Phase 3 EVOKE-03 trial in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (Pembrolizumab) in PD-L1-high Metastatic Non-small Cell Lung Cancer.

Last year, Gilead reported what it said were promising topline results from the EVOKE-02 study of Trodelvy in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and chemo in patients ...